Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY736 in relapsed/refractory CLL
NCT02137889Phase 1Terminated
- Sponsor
- Novartis
- Start
- Jul 2012
- Primary completion
- Nov 2012
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of ianalumab in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Novartis. Primary endpoint: Dose Limiting Toxicities at 8 months. Started Jul 2012; status: terminated.
02
Drugs
ianalumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02137889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02137889.